Ultragenyx Pharmaceutical RARE Net Income
Net Income at other companies
Other financials
Where this comes from
Reported directly by Ultragenyx Pharmaceutical in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The official record: Ultragenyx Pharmaceutical’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ultragenyx Pharmaceutical's net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ultragenyx Pharmaceutical's net income?
- Ultragenyx Pharmaceutical (RARE) reported net income of -$185M in Q1 2026.
- How has Ultragenyx Pharmaceutical's net income changed year-over-year?
- Ultragenyx Pharmaceutical's net income decreased by 22.5% year-over-year, from -$151M to -$185M.
- What is the long-term trend for Ultragenyx Pharmaceutical's net income?
- Over 4 years (2021 to 2025), Ultragenyx Pharmaceutical's net income has grown at a 6.1% compound annual growth rate (CAGR), from -$454.03M to -$574.92M.
- What does net income mean?
- The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.